Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$1.01
-1.9%
$1.17
$0.85
$4.22
$33.14M0.2224,882 shs14,231 shs
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.66
-2.4%
$1.77
$1.41
$5.01
$9.40M1.2948,895 shs42,900 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.73
+0.1%
$0.95
$0.72
$3.02
$30.81M2.85822,105 shs496,436 shs
MAAQ
Mana Capital Acquisition
$4.39
-4.2%
$4.11
$5.35
$10.25
$35.65MN/A33,075 shs15,812 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-2.42%-8.60%-12.55%-26.81%-72.92%
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-2.35%-12.17%-2.35%-10.27%-55.14%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+0.11%-8.79%-24.38%-33.45%-38.49%
MAAQ
Mana Capital Acquisition
0.00%-4.21%+21.53%+926.51%+893.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
2.6588 of 5 stars
3.55.00.00.00.03.30.0
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.7983 of 5 stars
3.55.00.00.00.60.81.3
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1.3721 of 5 stars
3.53.00.00.00.60.00.0
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
3.00
Buy$5.00395.05% Upside
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50833.73% Upside
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.001,129.51% Upside
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest APRE, ITRM, AKTX, and MAAQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
6/26/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
5/8/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$9.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A$0.84 per shareN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.50M6.12N/AN/A$3.55 per share0.47
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$19.79MN/A0.00N/AN/A-213.59%-65.60%8/18/2025 (Estimated)
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.99N/AN/AN/AN/A-71.37%8/5/2025 (Estimated)
MAAQ
Mana Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A

Latest APRE, ITRM, AKTX, and MAAQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2025Q2 2025
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$0.12N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.77N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/13/2025Q1 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.14-$0.14N/A-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/A
0.16
0.16
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.90
5.90
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
3.72
3.58
MAAQ
Mana Capital Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
5.06%
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
MAAQ
Mana Capital Acquisition
68.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
932.18 million19.92 millionNot Optionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.78 millionNo Data
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1042.13 million38.26 millionNot Optionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable

Recent News About These Companies

Decentraland (CRYPTO: MANA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.01 -0.02 (-1.94%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$1.01 +0.00 (+0.20%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.66 -0.04 (-2.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.70 +0.04 (+2.11%)
As of 08/1/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.73 +0.00 (+0.11%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.75 +0.02 (+2.60%)
As of 08/1/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mana Capital Acquisition NASDAQ:MAAQ

$4.39 -0.19 (-4.21%)
As of 07/25/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.